SASCeTS

Partow Kebriaei

Mohamad Mohty

Robert Zeiser

Alvaro Urbano-Ispizua

Justin Du toit

David Brittain

Martin Bornhaeuser

Matthew Seftel

Francesc Bosch

Jackie Thomson

Jackie Thomson

Siphiwe Baloyi

Farah Rahman

Partow Kebriaei

Partow Kebriaei, MD
Professor, Department of Stem Cell Transplantation and Cellular Therapy
MD Anderson Cancer Center
Houston, TX

Dr. Kebriaei received her BS degree from Yale University in 1993, and her MD degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000. She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia, as well as autologous and allogeneic stem cell transplantation for lymphoma and leukemia. She is interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, using umbilical cord blood in combination with a standard allogeneic peripheral blood stem cell transplant to augment the graft versus leukemia effect, and investigating the use of mesenchymal stem cells for the therapy of graft versus host disease. Dr. Kebriaei is the principal investigator of 10 currently active phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow

Mohamad Mohty

Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.
Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT . He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).

In addition to publishing more than 800 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International. He also serves as an editor, board member, and/or reviewer across numerous other reputable journals

Robert Zeiser

Prof. Robert Zeiser serves as Full Professor and Director of the Division of Tumor immunology of Medicine at the Freiburg University Medical Center. He serves as clinician with a focus on immunotherapy for cancer and allogeneic stem cell transplantation for leukemia. Prof. Zeisers laboratory research is focused on graft-versus-host disease, tumor immunology, in vivo imaging and oncogenic signaling. Prof. Zeiser authors more than 240 peer-reviewed publications and 14 book chapters. For his work Prof. Zeiser received several Science Awards in Germany, Europe and the United States. Prof Zeiser is the speaker of the Collaborative Research Center 1479 OncoEscape (SFB1479).

Alvaro Urbano-Ispizua

Director of the Hospital Clinic Institute of Hematology and Oncology, Clinical and
Provincial Hospital of Barcelona, Barcelona, Spain
Professor of Medicine, University of Barcelona, Barcelona, Spain

Dr Urbano-Ispizua areas of expertise are stem cell transplantation, cellular immunotherapy and haemato-oncology.

Dr Urbano-Ispizua previously served as the Head of the Research Unit of Cell Therapy and Stem Cell Transplantation at the Hospital Clinic of Barcelona, a unit which stands as one of the pioneers of bone marrow transplantation in Europe

Dr Urbano-Ispizua has authored and co-authored over 180 articles in internationally recognised, peer-reviewed journals such as Lancet, Journal of Clinical Oncology and Haematologica. He also serves a member of the editorial board of several journals

Justin Du toit

Justin is a clinical haematologist who trained at UCT and now works in the Bone Marrow Transplant Unit at Wits Donald Gordon Medical Centre. Together with his colleagues, they are busy implementing a quality management system in adult and paediatric bone marrow transplantation that will be JACIE-FACT accredited. His main focus and passion is bone marrow transplantation and is actively involved in research on haematopoietic stem cell mobilisation, haploidentical stem cell transplantation and donor specific antibodies. Through his research efforts, he strives towards creating best care algorithms to improve patient outcomes.

David Brittain

Dr David Brittain graduated his MB ChB in 1988 from the University of the Witwatersrand. He specialised in Haematopathology (1996) and super specialised in Clinical Haematology (1998) from the same university.

After running his own private practice in Johannesburg from 2000 – 2008 he joined the Alberts, Bouwer & Jordaan practice where he has worked as a Director in the Haematology and Cellular Therapy field.

He has a special interest in treating leukaemias, lymphomas and myeloma as well as stem cell transplantation. He is a Member of the South African Society of Haematology (SASH), the American Society of Hematology (ASH), the South African Myeloma Working Group and serves on the Executive Committee of the South African Stem Cell Transplant Society (SASCeTS).

In his spare time, he cycles, runs, rows, and does woodwork.

Martin Bornhaeuser

Throughout his clinical career Prof. Bornhäuser has focussed on translational research studies in the area of acute myeloid leukaemia and hematopoietic cell transplantation. He was one of the founding members of the Center of Regenerative Therapy Dresden (www.crt-dresden.de) and developed additional expertise in the areas of stem cell biology and adoptive cellular therapy. Professor Bornhäuser has a portfolio of responsibilities encompassing clinical service, being head of the Good manufacturing laboratories, coordinating translational reseach, lecturer in medical studies and in a master course for regenerative medicine and is an elected member of the internal medical faculty in Dresden. In 2015 he became a visiting professor at the department of haematology at King’s College London, UK. In 2016, he joined the directorate of the National Center for Tumor Diseases (www.nct-dresdden.de) in Dresden.

Matthew Seftel

Dr. Matthew Seftel is a Haematologist based at Canadian Blood Services (CBS), where he is a medical director for the Canadian Blood Services Unrelated Donor Stem Cell Registry and Cord Blood Bank. He is a clinical professor in the Division of Hematology, Department of Medicine, at the University of British Columbia, Vancouver, Canada and is also an Honorary Professor at the University of Cape Town, South Africa.

Dr Seftel qualified in Medicine from the University of Cape Town South Africa , with subsequent specialist Internal Medicine and Hematology training in the United Kingdom and Canada. He has further training in Leukemia/BMT fellowship from the BC Cancer Agency/University of British Columbia. Dr Seftel also completed a Masters in Public Health from Johns Hopkins University.

Dr. Seftel has had an academic career with focus on clinical outcomes in complex haematological malignancies and BMT. Prior to joining CBS he was in full time academic practice in adult leukemia/BMT for 20 years. He is an investigator with CIBMTR, Cellular Therapy and Transplant Canada (CTTC), and has been an clinical investigator with the Canadian Cancer Trials Group (CTTC). Under the auspices of CTTC and ASTCT he co-led the 2018 “Choosing Wisely” BMT campaign. He has received several teaching awards for his skills in undergraduate and graduate level education.

Francesc Bosch

Francesc Bosch is Professor of Hematology, Head of the Department of Hematology in University Hospital Vall d’Hebron, Barcelona, and Head of the Department of Hematology in IOB Institute of Oncology.

Professor Bosch graduated from Medical School in the University of Barcelona 1988. In 1997 he was awarded a PhD by the University of Barcelona for his research about the over-expression of Cyclin D1 in chronic lymphoproliferative disorders under the supervision of Professor Elias Campo. He subsequently did a two-year postdoctoral stay in the laboratory of Professor Riccardo Dalla-Favera at the Institute of Cancer Genetics, Columbia University, New York. He moved back to Hospital Clinic in Barcelona in 2000 where he continued doing research in CLL.

In September 2009, Prof Bosch became Head of the Department of Hematology and Director of the Experimental Hematology Laboratory at the University Hospital Vall d’Hebron in Barcelona.

Professor Bosch is one of the most internationally reputed leaders in Chronic Lymphocytic Leukemia (CLL). He conducts both clinical and basic research in CLL and other lymphoproliferative disorders, particularly focusing in the molecular pathogenesis of CLL and in the development of novel therapeutic approaches. Since 1995 he has been involved in the development of clinical trials in CLL, performing several contributions in the prognosis assessment and treatment of CLL.

Professor Bosch is currently chairing the Spanish CLL Working Group (GELLC), responsible for the development of Spanish CLL Clinical trials. He has published more than two hundred papers in peer-reviewed journals including high-impact ones such as The New England Journal of Medicine, Nature Medicine, Cancer Cell, Blood, Journal of Clinical Oncology, and Leukemia. In addition, he has authored or co-authored several Reviews and Book Chapters on the subject of CLL and other lymphoproliferative disorders.

Jackie Thomson

Dr Jackie Thomson is a clinical haematologist whose main area of interest is the treatment of blood disorders/malignancies. She is an expert in bone marrow transplantation and stem cell transplantation. She is the first Transplant Program Director in South Africa to achieve accreditation for by the European Bone Marrow Transplant Society by obtaining JACIE accreditation for a transplant unit. She is passionate about improving patient outcomes and does so by following best practices and implementing quality systems of international standards. She was previously the Medical Director of the South-African National Blood service and is currently Transplant Director at Wits Donald Gorden Medical Centre.

Siphiwe Baloyi

Dr Siphiwe Baloyi is a recent appointee to the Clinical Haematology Programme at the University of Cape Town, South Africa, based at Groote Schuur Hospital. A Haematopathologist by training, he retains a great interest in translational research, and his interests lie in HIV-related lymphoma, and transfusion medicine, working on ways to improve quality of care and diagnosis in the South African setting.

Farah Rahman

Dr Farah Rahman completed her undergraduate training at the University of the Witwatersrand in 2009; thereafter qualifying as a specialist physician in 2017 and completing her MMed in 2018. Farah joined the Clinical Haematology team of “Bara” as a fellow in 2018 and obtained her certificate in Clinical Haematology in 2020. She joined the Clinical Haematology team at Inkosi Albert Luthuli Central Hospital as a consultant since January 2021. Farah intends to promote interest and improve knowledge of clinical haematology in the province; as well as assist in growing the province’s stem cell transplantation programmes.